中国生物医药公司10亿美元规模量级的收购开了先河，这对于未来中国生物医药产业生态的发展有积极 意义，兼并重组加独立发展的模式。 7月16日，中国生物制药（1177.HK）股价开盘一度大涨近6%。前一日，中国生物制药公告，拟以不超 过9.51亿美元的总价全资收购创新药公司礼新医药。 有业内人士向第一财经记者评价道，这起收购开辟了中国以仿制药研发为主的成熟型生物医药公司 （biopharma）收购以创新药研发为主的生物科技初创公司（biotech）的新时代。 例如，以大输液起家的科伦药业，就将旗下科伦博泰作为创新药的引擎拆分上市；恒瑞医药在上海成立 了全球创新与临床研究中心，自主研发创新药；石药集团也正通过国际化的研发团队和实行中美、中欧 双报模式，加速创新药的研发上市。 微芯生物董事长鲁先平向第一财经记者表示："中国生物医药公司10亿美元规模量级的收购确实是开了 先河，这对于未来中国生物医药产业生态的发展有积极意义，兼并重组加独立发展的模式。" 跨国企业对中国生物技术公司类似规模量级的收购发生在去年11月，德国生物技术公司BioNTech宣布 以8亿美元收购中国生物技术公司普米斯生物。如果达到某些里程碑，普米斯 ...

（原标题：数据复盘丨汽车、医药生物等行业走强 龙虎榜机构抢筹11股） 7月16日，上证指数全天窄幅震荡；深证成指、创业板指早盘冲高回落，午后持续回落；科创50指数早盘冲高回落，午后窄幅震荡。截至收盘，上 证指数报3503.78点，跌0.03%，成交额5724.19亿元；深证成指报10720.81点，跌0.22%，成交额8696.23亿元；创业板指报2230.19点，跌0.22%，成 交额4290.19亿元；科创50指数报997.63点，涨0.14%，成交额268.93亿元。沪深两市合计成交14420.42亿元，成交额较上一交易日减少1700.22亿 元。 汽车、医药生物等行业走强 上纬新材6连板 盘面上来看，行业板块、概念涨多跌少。其中，汽车、医药生物、教育、轻工制造、纺织服饰、农林牧渔、塑料制品、机械设备等行业涨幅靠 前；同步磁阻电机、盲盒经济、创新药、地热能、宠物经济、中药、工业大麻、人形机器人、短剧互动游戏等概念走势活跃。保险、钢铁、银 行、有色金属、建筑材料、煤炭等行业跌幅居前；低碳冶金、PCB、复合集流体、钛白粉、稀土永磁、锂矿等概念走势较弱。涨停个股主要集中 在汽车、医药生物、机械设备、轻工制造、 ...

人形机器人"明星企业"智元机器人的掌门人邓泰华拟通过旗下持股平台，以每股7.78元的价格协议受让上纬新材29.99%的股份及对应表决权，并同步启动要 约收购，计划增持1.49亿股。若上述交易完成，邓泰华将合计控制上纬新材66.99%股权。此举被市场视作机器人"借壳"风电。 此外，宇树科技创始人王兴兴在"新征程上的奋斗者"中外记者见面会上表示，去年发布的G1这款人形机器人在全球范围内受到广泛关注，今年出货量相对 去年有明显增长。 7月16日，三大指数震荡回落，截至收盘，沪指跌0.03%，深成指跌0.22%，创业板跌0.22%，科创50指数涨0.14%，两市超3100只个股上涨，沪深两市今日成 交额约1.44万亿元。 医药板块堪称全场"最靓的仔"，其中，广生堂（300436.SZ）涨16.55%，我武生物（300357.SZ）涨15.9%，千红制药（002550.SZ）、前沿生物 （688221.SH）、科兴制药（688136.SH）均大涨。 国家医保局近日消息，第十一批国家组织药品集中采购工作日前启动。本次集采坚持"集采非新药、新药不集采"的原则，也就是说临床使用成熟的"老药"才 会纳入集采范围，创新药不会被纳 ...

近期，A 股2025年中报预告密集披露。截至7月15日，共有775家深市公司披露2025年半年度业绩预告， 其中，453家公司预计2025年上半年净利润实现同比增长（在上市公司披露的预测净利润同比增长上、 下限中，取较大绝对值），占比约58.45%。 具体来看，预计净利润同比增长超过30%、50%、100%的公司家数分别为405家、355家、204家（含扭 亏为盈的公司），占比约53%、46%、27%。 截至记者发稿，深市市值前100公司中，已有21家披露业绩预告，其中20家实现同比增长，预计合计实 现净利润512亿元至569亿元，持续领跑深市市场，龙头公司在较高利润规模水平上持续稳健增长。牧原 股份、新易盛、TCL科技等公司实现盈利且净利润增长超过100%；牧原股份预计实现净利润超过100亿 元，立讯精密预计实现净利润超过60亿元。 电子行业59家公司披露业绩预告，预计合计实现净利润125亿元-144亿元，沪电股份预计实现净利润 16.5亿元-17.5亿元，同比增长约53.4%；鹏鼎控股预计实现净利润12亿元-12.6亿元，同比增长约 60.62%；TCL科技预计实现净利润18亿元-20亿元，同比增长约10 ...

Core Viewpoint - The recent favorable policies have ignited interest in innovative drugs, leading to a surge in Guangshengtang's stock price, despite the company facing four consecutive years of net losses from 2021 to 2024 [1][7]. Fundraising and Investment Plans - Guangshengtang has announced a fundraising plan of 977 million yuan, with over 60% allocated to the development of two innovative hepatitis B drugs [1][2]. - The company plans to invest 598 million yuan in innovative drug research and development, with a total project investment of 631 million yuan [2][3]. - The fundraising will also allocate 884.9 million yuan for traditional Chinese medicine industrialization and 290 million yuan for working capital [2][3]. Clinical Trials and Drug Development - The innovative drug projects include clinical trials for GST-HG141 and GST-HG131, both targeting chronic hepatitis B treatment, with no competing products registered [3][8]. - GST-HG141 has been included in the breakthrough therapy list by CDE, while GST-HG131 is part of a pilot project for optimizing clinical trial reviews [3][8]. Financial Performance and Challenges - Guangshengtang's financial performance has been declining, with revenues of approximately 370 million yuan, 386 million yuan, 423 million yuan, and 441 million yuan from 2021 to 2024, while net losses were 35 million yuan, 127 million yuan, 349 million yuan, and 156 million yuan respectively [7]. - The company attributes its losses to the transition from generic to innovative drugs, ongoing R&D investments, and the impact of national drug procurement policies [7][8]. Previous Fundraising Issues - Previous fundraising efforts in 2020 and 2023 faced challenges, with projects either underperforming or being terminated due to economic viability concerns [9][10]. - The 2020 fundraising for a raw material drug production base did not yield expected results, leading to a significant loss of investment [9][10]. Regulatory Scrutiny - Regulatory authorities have requested explanations regarding the background of Guangshengtang's 2023 capital increase and whether it involves "hidden debt" scenarios [4][6]. - The company has defended its position, stating that the investment is purely equity-based and not a form of disguised debt [6].

智通财经APP获悉，港股今日冲高回落，三大指数午后集体转跌。截止收盘，恒生指数跌0.29%或72.36 点，报24517.76点，全日成交额为2589.51亿港元；恒生国企指数跌0.18%，报8861.39点；恒生科技指数 跌0.24%，报5418.4点。 申万宏源表示，持续看好港股以及A股市场的投资机会，在未来全球金融秩序重构的过程中，中国香港 将扮演重要角色，港股优质资产繁荣度预计不断提升，成为本土在岸资金+全球新秩序下的核心资本市 场。 蓝筹股表现 安踏体育(02020)领涨蓝筹。截至收盘，涨2.28%，报91.85港元，成交额13.2亿港元，贡献恒指4.55点。 安踏体育公布，2025年二季度，安踏品牌、FILA品牌流水分别同比增长低单位数、中单位数，所有其 他品牌流水同比增长50-55%。上半年， 安踏、FILA、其他品牌零售金额同比分别取得中单位数、高单 位数、60-65%的正增长。 其他蓝筹股方面，快手-W(01024)涨2.13%，报69.6港元，贡献恒指6.9点；携程集团-S(09961 )涨1.59%， 报498.2港元，贡献恒指3.36点；申洲国际(02313)跌2.75%，报56.6港 ...

Market Overview - The market experienced fluctuations with all three major indices closing lower, with the Shanghai Composite Index down 0.03%, Shenzhen Component Index down 0.22%, and ChiNext Index down 0.22 [1] - Sectors such as chemical pharmaceuticals, automotive parts, and oil showed gains, while insurance, steel, and energy metals sectors faced declines [1] Pharmaceutical Industry Insights - The National Healthcare Security Administration announced the initiation of the 11th batch of centralized drug procurement, including 55 products, with results expected to be published between October and November 2025 [1] - Institutions are optimistic about the overall recovery opportunities in the innovative drug sector, particularly following the adjustment of the national medical insurance and commercial health insurance drug directories [2] Automotive Industry Developments - As of July 11, 2025, the proportion of new energy vehicles (NEVs) in China's automotive market reached 10%, with an expected total NEV sales of 16 million units this year, and NEV sales are projected to exceed 50% of total new car sales [2] - Continuous release of new models and sustained consumer demand are expected to keep the automotive market performance strong, with a focus on low-valuation leading companies in the electric and intelligent vehicle sectors [3] Hong Kong Market Outlook - The Hong Kong stock market is anticipated to experience a structural upward trend, with overall valuations remaining relatively low and long-term investment value being high [3] - The ongoing reform of the listing system in Hong Kong is expected to enhance asset quality and liquidity, potentially attracting more southbound capital [3]

近日，益方生物在回复上交所关于2024年年报的信披监管问询函时披露，贝达药业拖欠其肺癌1类创新 药贝福替尼的里程碑款项1.8亿元，逾期时间已近2年。益方生物表示，通过邮件、电话、线下拜访等方 式与贝达药业多次沟通，并于2024年底发出正式催款函，但款项仍未到账。截至2024年末，益方生物已 按10%的坏账率计提坏账准备1800万元。 贝达药业拖欠益方生物1.8亿元的里程碑付款纠纷，不仅揭开了双方合作背后的生存压力，也让外界得 以窥见创新药BD（授权合作）交易中不为人知的履约困境，同时引发创新药行业对BD交易信用体系的 广泛讨论。经济学家、新金融专家余丰慧在接受《华夏时报》记者采访时表示，"益方生物与贝达药业 的付款拖延纠纷虽然引起了关注，但这并不意味着类似的付款纠纷已经成为国内创新药领域授权合作中 的普遍现象。然而，这一案例确实揭示了在BD交易合作模式上存在的一些问题和风险点。" 贝达药业1.8亿元欠款拉锯战 事件的起因源自于2018年12月，益方生物与贝达药业就肺癌创新药BPI-D0316（甲磺酸贝福替尼）的合 作达成共识，双方约定在合作区域（涵盖中国内地及港、台地区）内推进该产品的研发与商业化。合作 协议 ...

随着基金二季报陆续披露，多只基金产品规模呈现爆发式增长，部分"迷你基"上演惊人逆转。其中，长 城医药产业精选混合基金规模从一季度末的0.36亿元猛增至二季度末的11.32亿元，增幅超30倍，成为当 季耀眼黑马之一。 面对二季度震荡行情，主动权益基金经理普遍选择提升进攻性。长城医药产业精选混合权益仓位从 72.48%升至75.89%，重点加码创新药板块，三生制药、石药集团新晋前十大重仓股。同泰远见混合权 益仓位从78.65%提升至85.74%，前十大重仓股均为北交所上市公司。 重仓股"大换血"成为多家基金公司的共同选择。永赢基金旗下产品操作尤为激进：永赢科技智选的前十 大重仓股全部换新，持仓名单包括新易盛、中际旭创、天孚通信、胜宏科技、源杰科技、长芯博创、沪 电股份、工业富联、太辰光、深南电路。 永赢医药健康同样大幅调整持仓，最新前十大重仓股分别为舒泰神、热景生物、益方生物、泰恩康、奥 赛康、康辰药业、荣昌生物、神州细胞、迪哲医药、汇宇制药。舒泰神、热景生物、益方生物等创新药 企跻身前十。 值得注意的是，中欧数字经济混合前十大重仓股更换显著，新易盛再度被重点配置——该股曾在2024年 第三季度成为其第一大重仓股 ...

Core Viewpoint - The A-share market showed positive performance in the first half of the year, with the Shanghai Composite Index rising by 2.76%, and the North China 50 Index soaring by 39.45%, reaching a historical high. Various sectors such as AI models, humanoid robots, new consumption, innovative drugs, and solid-state batteries attracted significant investment [3][4]. Group 1: Market Performance - The average return of 4,200 products with performance data was approximately 10.07%, with 3,539 products showing positive returns, accounting for 84.26% [4]. - The quantitative long strategy and subjective long strategy led the performance in April, with average returns of 17.54% and 11.57%, respectively [4]. Group 2: Private Equity Insights - As of June 2025, the top 100 private equity firms had 593 products with a total scale of approximately 71.23 billion, achieving an average return of 24.08% in the last six months [5][6]. - The top five private equity firms included Nengjing Investment Holdings, Tongben Investment, Luyuan Private Equity, Chenyao Private Equity, and Youbo Capital [6]. Group 3: Strategy Performance - The performance of various strategies showed significant differences, with the subjective long strategy achieving an average return of ***% and a high positive return ratio [4][11]. - The top private equity firms maintained a focus on new consumption, which contributed to their strong performance in the first half of the year [11][20]. Group 4: Notable Private Equity Firms - Nengjing Investment Holdings led the performance with an average return of ***% from five products, while Tongben Investment and Fusheng Asset also performed well, focusing on new consumption [11][20]. - The private equity landscape included a mix of quantitative and subjective strategies, with a notable presence of firms that combined both approaches [5][12].